dihexa clinical trials humans First-In-Human Trial Requirement -BioPharma Services dihexa clinical trials humans Sublingual

Its small molecular weight (~505 Da) and lipophilic character support oral capsule administration consistent with the published research literature

Limitations of Current Research No human trials: All existing data comes from animal studies or anecdotal self-experimentation

Therefore, roles and mechanism of catecholamine excess for the pathogenesis of TTC have been extensively investigated, mainly focused on adrenergic stimulation and -adrenoceptor signaling

The capsule format reflects the orally active, BBB-permeable design that distinguishes Dihexa from its parent peptide angiotensin IV

Angiotensin II-(3-8)-hexapeptide affects motor activity, performance of passive avoidance and a conditioned avoidance response in rats